Cara Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 16:01 ET
|
Cara Therapeutics
– Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase 2 Meeting –
– Reported positive top-line data from...
Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine's 31st Annual Meeting
March 19, 2015 17:00 ET
|
Cara Therapeutics
Pain experts to discuss latest kappa opioid agonist data and the future of pain management
Company to present positive data from Phase 2 trial of I.V. CR845 during poster sessions...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
March 19, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
March 13, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., March 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa Opioid Receptor Agonist CR845 and Analogs for the Treatment and Prevention of Pain-Related Conditions
February 10, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference
February 02, 2015 07:01 ET
|
Cara Therapeutics
SHELTON, Conn., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index
December 18, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively...
Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
December 17, 2014 08:00 ET
|
Cara Therapeutics
I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis
Effective itch reduction seen in subgroup of patients with uremic...
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
December 02, 2014 08:05 ET
|
Cara Therapeutics
SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
December 02, 2014 08:00 ET
|
Cara Therapeutics
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
Establishes dosing range and regimen for Phase 2 trial design...